Treatment adherence in chronic myeloid leukaemia patients receiving tyrosine kinase inhibitors (Q33603379)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28444623%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

title

Treatment adherence in chronic myeloid leukaemia patients receiving tyrosine kinase inhibitors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28444623%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

1 reference

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28444623%20AND%20SRC:MED&resulttype=core&format=json

Agnieszka Kołkowska-Leśniak

18 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28444623%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28444623%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Ewa Lech-Marańda

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28444623%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Piotr Jerzmanowski

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28444623%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Adam Hołub

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28444623%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Zofia Specht-Szwoch

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28444623%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Violetta Kalinowska

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28444623%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Urszula Tęgowska

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28444623%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Ilona Seferyńska

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28444623%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

publication date

25 April 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28444623%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28444623%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28444623%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28444623%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

page(s)

104

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28444623%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 4.0 International

18 March 2020

start time

25 April 2017

1 reference

April 2022 Public Data File from Crossref

copyrighted

0 references

cites work

Increased adherence eight months after switch from twice daily calcineurin inhibitor based treatment to once daily modified released tacrolimus in heart transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5405100

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5405100

Adherence in severe asthma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5405100

Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5405100

Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5405100

Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5405100

Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5405100

Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5405100

Perspectives on Adherence and Persistence With Oral Medications for Cancer Treatment

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5405100

Patient counseling program to improve the compliance to imatinib in chronic myeloid leukemia patients

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5405100

Bosutinib: a dual SRC/ABL kinase inhibitor for the treatment of chronic myeloid leukemia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5405100

21 June 2018

Cancer statistics, 2010

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5405100

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5405100

Adjuvant hormonal therapy use among insured, low-income women with breast cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5405100

Patient adherence and persistence with oral anticancer treatment

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5405100

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5405100

Medication nonadherence: an unrecognized cardiovascular risk factor

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5405100

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5405100

Chronic myeloid leukaemia as a model of disease evolution in human cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5405100

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5405100

21 June 2018

Adherence to Medication

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5405100

Development of a structural model explaining medication compliance of persons with schizophrenia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5405100

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5405100

Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib era.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5405100

JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5405100

Adherence to therapy with oral antineoplastic agents

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5405100

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5405100

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5405100

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5405100

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

21 June 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-017-0958-6

Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-017-0958-6

Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-017-0958-6

Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-017-0958-6

The impact of compliance with osteoporosis therapy on fracture rates in actual practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-017-0958-6

Antiparkinson drug use and adherence in medicare part D beneficiaries with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-017-0958-6

Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-017-0958-6

Early discontinuation of tamoxifen: a lesson for oncologists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-017-0958-6

Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-017-0958-6

The effect of compliance with treatment on survival among patients with hematologic malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-017-0958-6

A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-017-0958-6

Adherence and persistence among chronic myeloid leukemia patients during second-line tyrosine kinase inhibitor treatment.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5405100

Relative prognostic value of self-reported adherence and plasma NNRTI/PI concentrations to predict virological rebound in patients initially responding to HAART.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5405100

Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy

30 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28444623

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S12032-017-0958-6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28444623%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

18 March 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28444623%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

PubMed publication ID

28444623

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28444623%20AND%20SRC:MED&resulttype=core&format=json